Navigation Links
BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology
Date:11/2/2009

WOBURN, Mass., Nov. 2 /PRNewswire/ -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2 clinical study of OncoVEX (GM-CSF) for the treatment of advanced melanoma has been published in the Journal of Clinical Oncology (JCO). The previously announced top line results report a high objective durable response rate and a high complete response rate, combined with a relatively benign side effect profile. Overall, 20% of patients ultimately achieved a complete response and 28% of patients achieved an overall objective response (complete response or partial response). Ninety two percent of the responses are durable as defined as lasting at least 6 months, and the majority are ongoing, with a range of 18 to 40 months. Responses were observed in patients with all stages of disease, including the complete resolution of visceral deposits. The study results were made available online today on the JCO website and will be published in the December 2009 print edition. The Phase 2 study was led by Dr. Neil N. Senzer of The Mary Crowley Cancer Research Center, Dallas, TX.

"The high percentage of durable complete responses in this study suggests that this therapy has the potential to provide long term benefit to responding patients, potentially including cures," said Dr. Neil N. Senzer of The Mary Crowley Cancer Research Center, Dallas, TX. "OncoVEX (GM-CSF) offers significant promise in providing a real advance in the treatment of a disease where there are few if any effective treatment options, particularly when coupled with a relatively benign side effect profile."

"In addition to use in more advanced patients, these encouraging results suggest OncoVEX (GM-CSF) has the potential to be used to intervene in the early stages of metastatic disease where it might act to reduce the high rate of progression to widespread diseas
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
2. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
3. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
4. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
5. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
6. PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
7. Arcadia Resources Announces Webcast of Its Fiscal 2010 Second Quarter Conference Call
8. ATS Medical Announces First in World Human Robotic Endoscopic Aortic Valve Replacement
9. Nuevolution Announces Receipt of Milestone Payment From Merck & Co., Inc.
10. Stryker Announces Change in Chairman of the Board of Directors
11. Cardica Announces Fiscal 2010 First Quarter Financial Results and Business Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... 14 Fujirebio Diagnostics Inc., a Malvern-based ... the Year by the Eastern Technology Council at ... in Philadelphia on Thursday, December 3, 2009. ... Philadelphia region,s largest technology and life sciences trade ... Technology and Life Sciences Community, the awards are ...
(Date:12/14/2009)... Calif., Dec. 14 Alexza Pharmaceuticals, Inc. (Nasdaq: ... its New Drug Application (NDA) for Staccato® loxapine (AZ-004) ... AZ-004 is an inhalation product candidate being developed for ... or bipolar disorder. The IND for Staccato ... 2005. ,, "AZ-004 has delivered a predictable and consistent ...
(Date:12/14/2009)... Zargis Medical Corp., a majority-owned subsidiary ... a spin-off from Siemens Corporate Research (NYSE: ... begun selling its award-winning Zargis Cardioscan(TM) system on ... its accompanying Bluetooth®-enabled electronic stethoscope were jointly named ... Innovation of the Year." Cardioscan is the ...
Breaking Medicine Technology:Fujirebio Diagnostics Named Life Sciences Company of the Year 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2MHA Announces Gloria Barr Esq as Vice President 26 General Counsel 54636 1MHA Announces Gloria Barr Esq as Vice President 26 General Counsel 54636 2Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 1Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 2Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 3Nucleix Researchers Discover DNA Evidence May Easily be Falsified 3A Company Develops New Detection Technology for Preventing Biological Identity The 13594 4Department of Health Releases Guidance on Novel H1N1 Influenza for Schools K 12 54633 1Department of Health Releases Guidance on Novel H1N1 Influenza for Schools K 12 54633 2Department of Health Releases Guidance on Novel H1N1 Influenza for Schools K 12 54633 3
... Cardium Therapeutics,(Amex: CXM ) and ... that,positive findings from a preclinical study, demonstrating ... hyperthermia (cooling) for the potential,treatment of acute ... by BioMed Central (BMC) Cardiovascular Disorders (2008, ...
... Assess Feasibility of Dose-sparing and ... Vaccination Against H5N1 Flu -, GAITHERSBURG, Md., April 15 ... has received approval from the,Department of Health and Human Services ... for use with an injected H5N1,influenza vaccine. This decision was ...
Other Medicine Technology:Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 2Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 3Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 4Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 5Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 6Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 7Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 8Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 9Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 10Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 11Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 12Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch 2Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch 3Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch 4
(Date:12/14/2009)... Heska Corporation (Nasdaq: HSKA ; "Heska" ... veterinary diagnostic and specialty products, today announced ... new DRI-CHEM® 7000 Veterinary Chemistry Analyzer (the ... ,, Customers receiving these analyzers have invested ... available to the veterinary in-clinic market. ...
(Date:12/14/2009)... National Organization for Rare Disorders (NORD) today called upon ... annual health insurance caps. In a full-page ad ... on Capitol Hill, NORD said the current Senate health ... continue for most Americans, contrary to what many people ... welcomes the promises made by President Obama and Congress ...
(Date:12/14/2009)... say , , MONDAY, Dec. 14 (HealthDay News) -- U.S. ... single gene linked to heart failure. , The team ... analyzed the DNA of a large group of white ... four genes that could be connected with heart failure. ... 625 healthy whites led the researchers to identify 12 ...
(Date:12/14/2009)... , ... La Jolla, Calif. (Vocus) -- The physicians at ... the new chief of staff of the 372-bed facility. Dr. Sedwitz ... Jan. 1, 2010. , , , , ,During his two-year term, ... Jolla’s administrative staff and its board of directors. Dr. Sedwitz will ...
(Date:12/14/2009)... Pasierb, President ,, NEW YORK, Dec. 14 ... the Future study (MTF) -- the largest survey on ... 12th graders -- underscores that teens, intentional abuse of ... a cause for concern, with an alarming number of ... relatives. ,, Teen Abuse of Medication ...
Breaking Medicine News(10 mins):Health News:Heska Announces Installation of New Chemistry Analyzer 2Health News:Heska Announces Installation of New Chemistry Analyzer 3Health News:NORD Calls for Immediate End to Lifetime Insurance Caps 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3
... have carried out the world's first successful heart surgery to ... operation was performed at Siriraj Hospital on February 20 by ... than 50 days later the separated twins were still in ... the world that doctors have successfully separated Siamese twins joined ...
... been accused of being institutionally racist. In this week’s ... pioneers in moving towards equity, they have some way ... multi-cultural society. ,The "Count me in" census, ... reading for people of African and Caribbean origin living ...
... of prostate-specific antigen (PSA) in a man’s bloodstream at ... rate of change over the course of the disease// ... a study in the April 4 Journal of the ... localized prostate cancer have high long-term survival rates, many ...
... epidemic, a leading obstetricians has warned//. ,"Any ... With Caesarean this is the risk if the procedure is ... former Director of the Dublin-based National Maternity Hospital, which is ... ,Speaking at a seminar in New Delhi, he said ...
... closer to menopause tend to have a reduced risk ... treatment// further from menopause, according to a study. ... postmenopausal hormone therapy on coronary heart disease (CHD) have ... conducted. There may be a number of reasons for ...
... leading organization of conscientious and concerned doctors, has issued an ... has brought against India, demanding a patent for one of ... drug firms have a habit of making minor improvements in ... ,India has been saying the products are not new ...
Other Medicine News:Health News:Chances of Tackling Racism in Mental Health Care is Still Remote 2Health News:PSA Not a Good Predictor of Lethal Prostate Cancer 2Health News:'Alarming Rise in Caesarean Births a Cause of Concern' 2Health News:Starting Time of Hormone Therapy may Augment the Risk of Coronary Heart Disease 2Health News:People Before Patents 2
... B6 makes it possible to determine the,vitamin ... method. The kits includes all reagents in,ready ... of the samples with,exception of the columns. ... simultaneous handling of many analytes in a ...
ELISA kit for the quantitative determination of autoantibodies to tissue transglutaminase (tTG) in serum....
... Increased volume for use with 4, 8, or ... permits withdrawal of nearly all of the solution. ... solution. Made of natural virgin polystyrene containing no ... Sterilized by irradiation. Dimensions: 78 mm W x ...
Volume: 25 ml; Volume Graduation: 2/10 ml...
Medicine Products: